Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Stopped early · Phase 2

Conditions studied: Platinum-resistant Epithelial Ovarian Cancer

In brief

Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.

Key facts

Study ID

NCT05243524

Run by

ImmunoVaccine Technologies, Inc. (IMV Inc.)

People needed

16

Starts

2022-08-05

Expected to finish

2023-08-31

Last updated by the study team

2023-09-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Stanford Health Care — Palo Alto, California, United States
• Ocala Oncology — Ocala, Florida, United States
• NYU Langone Hospital-Long Island — Mineola, New York, United States
• NYU Langone: Laura and Isaac Perlmutter Cancer Center — New York, New York, United States
• CHUM - Centre hospitalier de l'Université de Montréal — Montreal, Quebec, Canada
• PanOncology Trials — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.